The World Health Organization (WHO) has announced that the Solidarity PLUS trial for promising medications will be conducted in 52 countries, marking an unprecedented global partnership for COVID-19 R&D.
The WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, announced the second phase of the Solidarity study, Solidarity PLUS, which will enroll hospitalized patients to evaluate three novel medications in hospitalized COVID-19 patients.
The medicines artesunate, imatinib, and infliximab were chosen by an independent expert panel for their ability to reduce the risk of death in COVID-19 patients who were hospitalized.
Artesunate is used to treat severe malaria, imatinib is used to treat some cancers, and infliximab is used to treat immune system illnesses like Crohn’s disease and rheumatoid arthritis.
The manufacturers of these medications generously contributed them for the trial.
According to him, “Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need, and WHO is proud to lead this global effort.”
“I would like to thank the participating governments, pharmaceutical companies, hospitals, clinicians and patients, who have come together to do this in true global solidarity.”
“The Solidarity PLUS trial is a platform trial that represents the largest global collaboration among WHO Member States. It involves thousands of researchers in over 600 hospitals in 52 countries, 16 more countries than the first phase of trials.
“This allows the trial to assess multiple treatments at the same time using a single protocol, recruiting thousands of patients to generate robust estimates on the effect a drug may have on mortality even moderate effects.
It also allows new treatments to be added and ineffective treatments to be dropped throughout the course of the trial.
Previously, four drugs were evaluated by the trial. The results showed that remdesivir, hydroxychloroquine, lopinavir and interferon had little or no effect on hospitalized patients with COVID-19.
Through the Solidarity PLUS trial, researchers across the world have an opportunity to use their expertise and resources to contribute to global COVID-19 research.
While speaking on Artesunate, he said; “Produced by Ipca, is used to treat malaria. In the trial, it will be administered intravenously for 7 days, using the standard dose recommended for the treatment of severe malaria.
“Artesunate is a derivative of artemisinin, an antimalarial drug extracted from the herb Artemisia annua. Artemisinin and its derivatives have been extensively used in the treatment of malaria and other parasitic diseases for over 30 years, and are regarded as being very safe. The WHO COVID-19 Therapeutics Advisory Group recommended evaluating the anti-inflammatory properties of artesunate”.
Also talking on, Imatinib,he said, “Produced by Novartis, is used to treat certain cancers.
In the trial, it will be administered orally, once daily, for 14 days. The dose used is the standard maintenance dose, which is at the lower end of the dose patients with haematological malignancies are given over extended periods.
“Imatinib is a small molecule tyrosine kinase inhibitor, formulated as an oral chemotherapy drug used to treat certain types of cancer. Experimental and early clinical data suggest that imatinib reverses pulmonary capillary leak. A randomized clinical trial performed in the Netherlands reported that imatinib might confer clinical benefit in hospitalized COVID-19 patients, in the absence of safety issues”.
More so on Infliximab , he said, “Produced by Johnson and Johnson, is used to treat diseases of the immune system.
In the trial, it will be administered intravenously as a single dose. The dose used is the standard dose that patients with Crohn’s Disease are given over extended periods.
“Infliximab is a TNF alpha inhibitor, a chimeric monoclonal antibody that recognizes human TNF alpha. Anti-TNF biologics have been approved for treatment of certain autoimmune inflammatory conditions for more than 20 years, demonstrating favourable efficacy and safety in restricting broad spectrum inflammation, including in elderly populations who are most clinically vulnerable to COVID-19”.
